Multifunctional aldose reductase inhibitors based on 2H-benzothiazine 1,1-dioxide

RSC Advances ◽  
2016 ◽  
Vol 6 (16) ◽  
pp. 12761-12769 ◽  
Author(s):  
Zhongfei Han ◽  
Xin Hao ◽  
Zehong Gao ◽  
Bing Ma ◽  
Changjin Zhu

A series of benzothiazine derivatives were designed and synthesized for the development of drug candidates for diabetic complications.

Molecules ◽  
2021 ◽  
Vol 26 (10) ◽  
pp. 2867
Author(s):  
Lucia Kovacikova ◽  
Marta Soltesova Prnova ◽  
Magdalena Majekova ◽  
Andrej Bohac ◽  
Cimen Karasu ◽  
...  

Aldose reductase (AR, ALR2), the first enzyme of the polyol pathway, is implicated in the pathophysiology of diabetic complications. Aldose reductase inhibitors (ARIs) thus present a promising therapeutic approach to treat a wide array of diabetic complications. Moreover, a therapeutic potential of ARIs in the treatment of chronic inflammation-related pathologies and several genetic metabolic disorders has been recently indicated. Substituted indoles are an interesting group of compounds with a plethora of biological activities. This article reviews a series of indole-based bifunctional aldose reductase inhibitors/antioxidants (ARIs/AOs) developed during recent years. Experimental results obtained in in vitro, ex vivo, and in vivo models of diabetic complications are presented. Structure–activity relationships with respect to carboxymethyl pharmacophore regioisomerization and core scaffold modification are discussed along with the criteria of ‘drug-likeness”. Novel promising structures of putative multifunctional ARIs/AOs are designed.


1992 ◽  
Vol 54 (2) ◽  
pp. 151-194 ◽  
Author(s):  
David R. Tomlinson ◽  
Gary B. Willars ◽  
Anne L. Carrington

Author(s):  
Arun K. Gupta ◽  
Jyoti Pandey ◽  
Arshad Ali

ABSTRACTObjective: Aldose reductase (ALR) enzyme plays a significant role in conversion of excess amount of glucose into sorbitol in diabetic condition,inhibitors of which decrease the secondary complication of diabetes mellitus. Scarce treatment of diabetic complications has motivated our interestfor the search of new aldose reductase inhibitors (ARIs) endowed with more favorable biological properties.Methods: Newer (4-(benzamidobenzylidene)-2,4-dioxothiazolidin-3-yl) acetic acid derivatives were synthesized, and these compound wereevaluated for their ARI and antidiabetic activity.Results: ARI activity of synthesized compounds was found in the range of 57.8-71.9% at 5µg/mL. Similarly, synthesized compounds decrease bloodglucose level in the range of 64.4-70.5 mg/dl at 15 mg/kg body weight.Conclusion: (E)-2-(5-(4-(substituted benzamido)benzylidene)-2,4-dioxothiazolidin-3-yl)acetic acid analogs shows comparable ARI as well asantidiabetic activity. These new class of compounds might be address the diabetic complications with safety.Keywords: Aldose reductase inhibitors, Diabetes mellitus, N-acetic acid-2,4-thiazolidinediones. 


Sign in / Sign up

Export Citation Format

Share Document